<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618119</url>
  </required_header>
  <id_info>
    <org_study_id>11323</org_study_id>
    <nct_id>NCT05618119</nct_id>
  </id_info>
  <brief_title>[18F]MC225 PET to Evaluate Gender Differences in BBB P-gp Function</brief_title>
  <official_title>The Impact of Gender Differences in P-glycoprotein Function Measured With [18F]MC225 and PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      P-gp is one of the main efflux transporters at the blood-brain barrier and is responsible for&#xD;
      the transport of a variety of neurotoxic substances, including pharmaceuticals. Multiple&#xD;
      studies report gender differences in therapeutic outcomes, toxicity and side effects for many&#xD;
      drug agents. P-gp plays an important role in the bio-availability, drug distribution,&#xD;
      metabolism and elimination of pharmaceuticals labelled as P-gp substrates (e.g. the majority&#xD;
      of antidepressants and antipsychotics). A difference in P-gp function was already reported in&#xD;
      hepatic P-gp expression. The aim of the current study is to evaluate the influence of gender&#xD;
      on cerebral P-gp function. Outcomes of this study can be of great importance in gender-based&#xD;
      prescription of P-gp substrate pharmaceuticals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of healthy volunteers (5 male, 5 female)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET kinetic modeling outcome parameters [18F]MC225</measure>
    <time_frame>60 minutes after administration [18F]MC225</time_frame>
    <description>volume of distribution, K1, k2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET kinetic modeling outcome parameters [15O]H2O</measure>
    <time_frame>10 minutes after administration of [15O]H2O</time_frame>
    <description>K1 to evaluate Cerebral Blood Flow (CBF)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Gender</condition>
  <arm_group>
    <arm_group_label>Male</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 male participants will undergo a [18F]MC225 PET scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 female participants will undergo a [18F]MC225 PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]MC225</intervention_name>
    <description>[18F]MC225 PET scan</description>
    <arm_group_label>Female</arm_group_label>
    <arm_group_label>Male</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medication with a known effect on the BBB P-glycoprotein transporter&#xD;
&#xD;
          -  Any history of neurological or psychiatric conditions affecting the BBB P-glycoprotein&#xD;
             function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pascalle Mossel, Msc</last_name>
    <phone>+3150 361 6161</phone>
    <email>p.mossel@umcg.nl</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Gert Luurtsema</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>P-glycoprotein</keyword>
  <keyword>MC225</keyword>
  <keyword>[18F]MC225</keyword>
  <keyword>PET</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

